Pfizer is a leading pharmaceutical company in the research and development of antibiotics and anti-infectives, providing the world with infectious disease medications and treatment for nearly a century. Since our pioneering work on penicillin in the 1940s, we have a long and proud heritage of addressing evolving infectious disease challenges in Hong Kong and the rest of the world¹.
As one of the original signatory companies of the Declaration on Combating Antimicrobial Resistance (AMR) in 2016 ² and as a Global anti-infectives leader, we remain committed to the development of both innovative medicines and vaccines, as well as solutions that go beyond medicine.
As a leading pharmaceutical company in the field, we currently offer patients one of the industry's largest and most diverse portfolios of anti-infectives— more than 80 medicines — including therapies that help address areas of greatest unmet medical need, such as the treatment of Gram-negative bacterial and invasive fungal infections.
Our commitment to research and development (R&D) is focused on both the treatment and prevention of infections caused by difficult-to-treat resistant pathogens. We continue to evaluate opportunities and partnerships to expand our R&D pipeline to ensure we address the evolving medical needs of people and physicians in this important area of infectious disease.
When pathogens evolve and find ways to resist the effects of antimicrobial medicines, they also grow and spread their resistance to amplify the patient’s vulnerability at a devastating speed. This process of adaptation, known as AMR (Antimicrobial resistance), can make serious infectious diseases such as pneumonia and tuberculosis resistant to treatment, and many routine procedures could become too risky to perform. Even minor infections and injuries could become life-threatening for patients with AMR.
AMR can affect anyone of any age. It is a dangerous threat to global health care and a difficult challenge the global medical industry faces today. Every year, around 700,000 people lose their lives to AMR globally, and experts estimate that AMR could cause 10 million annual deaths by 2050, if our development of more advanced infection medication should fail³.
Progress in AMR research and development is more important than ever, because if no solution is found, the devastating impact is likely to worsen. In addition to our ongoing development of medication and treatments for infectious diseases, Pfizer has been allocating an increased portion of our resources and focus to AMR research and development.
Due to the huge expenses and risks involved in developing anti-infective medications, few pharmaceutical companies in the world retain an anti-infectives portfolio today. Despite the high costs and potentially low returns, Pfizer continues to be invested in this field and take on the responsibility of producing vital antibiotics and infection medications for patients in Hong Kong and the rest of the world. You can learn more about Pfizer’s philosophy and our research and developments here.
Pfizer annual review 2018. Available at: https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2018/assets/pdf/pfizer-2018-annual-review.pdf. Last accessed May 2022.
Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance. January 2016. https://amr-review.org/sites/default/files/Industry_Declaration_on_Combating_Antimicrobial_Resistance_UPDATED%20SIGNATORIES_MAY_2016.pdf. Last accessed May 2022.
Antimicrobial Resistance. Available at: https://www.pfizer.com/science/focus-areas/anti-infectives/antimicrobial-resistance. Last accessed May 2022.